Alberta Investment Management Corp Bristol Myers Squibb CO Transaction History

Alberta Investment Management Corp

$10.2 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $917,700 - $1.21 Million	-22,800 Reduced 47.6%	25,100 $1.04 Million
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $906,917 - $1.03 Million	-18,902 Reduced 28.3%	47,900 $2.6 Million
Q4 2023 Feb 12, 2024	BUY	$48.48 - $57.85 $916,368 - $1.09 Million	18,902 Added 39.46%	66,802 $3.43 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $6.84 Million - $7.76 Million	-104,067 Reduced 68.48%	47,900 $3.32 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $82,176 - $97,308	-1,200 Reduced 0.78%	151,967 $10.9 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $2,145 - $1.27 Million	16,500 Added 12.07%	153,167 $10.9 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $7.3 Million - $8.04 Million	100,467 Added 277.53%	136,667 $10.5 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $7.49 Million - $8.98 Million	-121,763 Reduced 77.08%	36,200 $2.64 Million
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $1.71 Million - $2 Million	31,978 Added 25.38%	157,963 $9.85 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $1.87 Million - $2.19 Million	-31,597 Reduced 20.05%	125,985 $7.46 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $1.42 Million - $1.55 Million	-23,003 Reduced 12.74%	157,582 $10.5 Million
Q1 2021 May 07, 2021	BUY	$59.34 - $66.74 $135,591 - $152,500	2,285 Added 1.28%	180,585 $11.4 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $594,722 - $673,929	-10,300 Reduced 5.46%	178,300 $11.1 Million
Q3 2020 Oct 26, 2020	SELL	$57.43 - $63.64 $4.74 Million - $5.25 Million	-82,500 Reduced 30.43%	188,600 $11.4 Million
Q2 2020 Aug 11, 2020	BUY	$54.82 - $64.09 $3.43 Million - $4.01 Million	62,600 Added 30.02%	271,100 $15.9 Million
Q1 2020 May 08, 2020	SELL	$46.4 - $67.43 $30.3 Million - $44.1 Million	-653,550 Reduced 75.81%	208,500 $11.6 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $18.7 Million - $24.3 Million	-379,150 Reduced 30.55%	862,050 $55.3 Million
Q3 2019 Oct 23, 2019	SELL	$42.77 - $50.71 $2.61 Million - $3.09 Million	-61,000 Reduced 4.68%	1,241,200 $62.9 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $24.5 Million - $27.1 Million	549,000 Added 72.89%	1,302,200 $59.1 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $13.6 Million - $16.2 Million	301,000 Added 66.56%	753,200 $35.9 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $10.4 Million - $13.5 Million	214,200 Added 90.0%	452,200 $23.5 Million
Q3 2018 Nov 16, 2018	BUY	$55.19 - $62.25 $11.9 Million - $13.4 Million	215,900 Added 976.92%	238,000 $14.8 Million
Q2 2018 Aug 15, 2018	BUY	$50.53 - $62.98 $1.12 Million - $1.39 Million	22,100 New	22,100 $1.22 Million
Q1 2018 May 16, 2018	SELL	$59.92 - $68.98 $635,152 - $731,188	-10,600 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$59.94 - $65.35 $1.51 Million - $1.65 Million	-25,200 Reduced 70.39%	10,600 $650,000
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $1.98 Million - $2.28 Million	35,800	35,800 $2.28 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$11.1 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.32 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.46 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.58 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.58 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Alberta Investment Management Corp with notifications on news.

Account